Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs

Journal of Translational Medicine

Volumn 7, Issue , 2009, Pages

  Aloysius, Mark M ^a   Mc Kechnie, Alastair J ^a   Robins, Richard A ^b   Verma, Chandan ^b   Eremin, Jennifer M ^c   Farzaneh, Farzin ^d   Habib, Nagy A ^e   Bhalla, Joti ^d   Hardwick, Nicola R ^d   Satthaporn, Sukchai ^a   Sreenivasan, Thiagarajan ^c   El Sheemy, Mohammed ^c   Eremin, Oleg ^a,c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c LINCOLN COUNTY HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; PEPTIDE VACCINE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA; CANCER VACCINE; HLA ANTIGEN CLASS 1; HLA D ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 6; PEPTIDE FRAGMENT; PROSTAGLANDIN E2; TELOMERASE;

ADULT; ADVANCED CANCER; AGED; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG CYTOTOXICITY; DRUG FEVER; DRUG HYPERSENSITIVITY; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHATIC DRAINAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MONOCYTE; REGULATORY T LYMPHOCYTE; SEPSIS; VEIN THROMBOSIS; CYTOTOXICITY; DRUG EFFECT; IMMUNOLOGY; LYMPH NODE; MACROPHAGE; NEOPLASM;

CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DINOPROSTONE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-D ANTIGENS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-1; INTERLEUKIN-6; LYMPH NODES; MACROPHAGES; NEOPLASMS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TELOMERASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65149088249     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-7-18     Document Type: Article

References (101)

1. Gilboa E DC-based cancer vaccines Journal of Clinical Investigation 2007, 117:1195-1203. 1857263 17476349
2. Mellman I Steinman RM Dendritic cells: Specialized and regulated antigen processing machines Cell 2001, 106:255-258. 11509172
3. Ardavin C del Hoyo GM Martin P Anjuere F Arias CF Marin AR Ruiz S Parrillas V Hernandez H Origin and differentiation of dendritic cells Trends In Immunology 2001, 22:691-700. 11739000
4. Kim HJ Yang JS Woo SS Kim SK Yun C-H Kim KK Han SH Lipoteichoic acid and muramyl dipeptide synergistically induce maturation of human dendritic cells and concurrent expression of proinflammatory cytokines Journal of Leukocyte Biology 2007, 81:983-989. 17210616
5. Chen Y Yang C Jin N Xie Z Tang Y Fei L Jia Z Wu Y Terminal complement complex C5b-9-treated human monocyte-derived dendritic cells undergo maturation and induce Th1 polarization European Journal of Immunology 2007, 37:167-176. 17171756
6. Uehori J Fukase K Akazawa T Uematsu S Akira S Funami K Shingai M Matsumoto M Azuma I Toyoshima K et al.: Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: Monoacylated MDP confers TLR2/TLR4 activation J Immunol 2005, 174(11):7096-7103. 15905553
7. Nakahara S Tsunoda T Baba T Asabe S Tahara H Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide Cancer Research 2003, 63:4112-4118. 12874015
8. Zobywalski A Javorovic M Frankenberger B Pohla H Kremmer E Bigalke I Schendel DJ Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70 Journal of Translational Medicine 2007, 5:18. 1858682 17430585
9. Figdor CG de Vries IJM Lesterhuis WJ Melief CJM Dendritic cell immunotherapy: Mapping the way Nature Medicine 2004, 10:475-480. 15122249
10. Thurner B Roder C Dieckmann D Heuer M Kruse M Glaser A Keikavoussi P Kampgen E Bender A Schuler G Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application[erratum appears in J Immunol Methods 1999 Apr 22;224(1-2):211] Journal of Immunological Methods 1999, 223:1-15. 10037230
11. Sallusto F Lanzavecchia A Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha Journal of Experimental Medicine 1994, 179:1109-1118. 2191432 8145033
12. Grassi F Dezutter-Dambuyant C McIlroy D Jacquet C Yoneda K Imamura S Boumsell L Schmitt D Autran B Debre P Hosmalin A Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules Journal of Leukocyte Biology 1998, 64:484-493. 9766629
13. Cella M Sallusto F Lanzavecchia A Origin, maturation and antigen presenting function of dendritic cells Current Opinion in Immunology 1997, 9:10-16. 9039784
14. Um H-D Cho Y-H Kim DK Shin J-R Lee Y-J Choi K-S Kang J-M Lee M-G TNF-alpha suppresses dendritic cell death and the production of reactive oxygen intermediates induced by plasma withdrawal Experimental Dermatology 2004, 13:282-288. 15140018
15. Iwamoto S Iwai S-i Tsujiyama K Kurahashi C Takeshita K Naoe M Masunaga A Ogawa Y Oguchi K Miyazaki A TNF-alpha drives human CD14+ monocytes to differentiate into CD70+ dendritic cells evoking Th1 and Th17 responses Journal of Immunology 2007, 179:1449-1457.
16. Keller AM Groothuis TA Veraar EAM Marsman M de Buy Wenniger LM Janssen H Neefjes J Borst J Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules Proceedings of the National Academy of Sciences of the United States of America 2007, 104:5989-5994. 1851604 17389361
17. Soares H Waechter H Glaichenhaus N Mougneau E Yagita H Mizenina O Dudziak D Nussenzweig MC Steinman RM A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo Journal of Experimental Medicine 2007, 204:1095-1106. 2118574 17438065
18. Ye Z Chen Z Sami A El-Gayed A Xiang J Human dendritic cells engineered to express alpha tumor necrosis factor maintain cellular maturation and T-cell stimulation capacity Cancer Biotherapy & Radiopharmaceuticals 2006, 21:613-622. 17257077
19. Babatz J Rollig C Oelschlagel U Zhao S Ehninger G Schmitz M Bornhauser M Large-scale immunomagnetic selection of CD14(+) monocytes to generate dendritic cells for cancer immunotherapy: A phase I study Journal Of Hematotherapy & Stem Cell Research 2003, 12:515-523. 14594508
20. Bender A Sapp M Schuler G Steinman RM Bhardwaj N Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood Journal Of Immunological Methods 1996, 196:121-135. 8841451
21. Eloranta ML Sandberg K RicciardiCastagnoli P Lindahl M Alm GV Production of interferon-alpha/beta by murine dendritic cell lines stimulated by virus and bacteria Scandinavian Journal Of Immunology 1997, 46:235-241. 9315110
22. Ferbas JJ Toso JF Logar AJ Navratil JS Rinaldo CR Cd4(+) Blood Dendritic Cells are Potent Producers of Ifn-Alpha in Response to In-Vitro Hiv-1 Infection Journal Of Immunology 1994, 152:4649-4662.
23. Luft T Pang KC Thomas E Hertzog P Hart DN Trapani J Cebon J Type I IFNs enhance the terminal differentiation of dendritic cells Journal of Immunology 1998, 161:1947-1953.
24. Paquette RL Hsu N Said J Mohammed M Rao NP Shih G Schiller G Sawyers C Glaspy JA Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo[see comment] Leukemia 2002, 16:1484-1489. 12145689
25. Radvanyi LG Banerjee A Weir M Messner H Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells Scandinavian Journal of Immunology 1999, 50:499-509. 10564553
26. Santini SM Lapenta C Logozzi M Parlato S Spada M Di Pucchio T Belardelli F Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice Journal of Experimental Medicine 2000, 191:1777-1788. 2193160 10811870
27. Ferrantini M Capone I Belardelli F Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use Biochimie 2007, 89:884-893. 17532550
28. Parlato S Santini SM Lapenta C Di Pucchio T Logozzi M Spada M Giammarioli AM Malorni W Fais S Belardelli F Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: Importance for the rapid acquisition of potent migratory and functional activities Blood 2001, 98:3022-3029. 11698286
29. Santodonato L D'Agostino G Nisini R Mariotti S Monque DM Spada M Lattanzi L Perrone MP Andreotti M Belardelli F Ferrantini M Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response Journal of Immunology 2003, 170:5195-5202.
30. Luft T Luetjens P Hochrein H Toy T Masterman KA Rizkalla M Maliszewski C Shortman K Cebon J Maraskovsky E IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells International Immunology 2002, 14:367-380. 11934873
31. McRae BL Nagai T Semnani RT van Seventer JM van Seventer GA Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14(+) precursors Blood 2000, 96(1):210-217. 10891453
32. Jonuleit H Kuhn U Muller G Steinbrink K Paragnik L Schmitt E Knop J Enk AH Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions European Journal of Immunology 1997, 27:3135-3142. 9464798
33. Sporri R Reis e Sousa C Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function[see comment] Nature Immunology 2005, 6:163-170. 15654341
34. Morelli AE Thomson AW Dendritic cells under the spell of prostaglandins Trends in Immunology 2003, 24:108-111. 12615202
35. Banerjee DK Dhodapkar MV Matayeva E Steinman RM Dhodapkar KM Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients Blood 2006, 108:2655-2661. 1895594 16763205
36. Satthaporn S Aloysius MM Robins RA Verma C Chuthapisith S McKechnie AJ El-Sheemy M Vassanasiri W Valerio D Clark D et al.: Ex vivo recovery and activation of dysfunctional, anergic, monocyte-derived dendritic cells from patients with operable breast cancer: Critical role of IFN-alpha BMC Immunol 2008, 9:32. 2447825 18588665
37. Padovan E Spagnoli GC Ferrantini M Heberer M IFN-alpha2a induces IP-10/ CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells Journal of Leukocyte Biology 2002, 71:669-676. 11927654
38. Cella M Salio M Sakakibara Y Langen H Julkunen I Lanzavecchia A Maturation, activation, and protection of dendritic cells induced by double-stranded RNA Journal of Experimental Medicine 1999, 189:821-829. 2192946 10049946
39. Carpenter EL Vonderheide RH Telomerase-based immunotherapy of cancer Expert Opinion on Biological Therapy 2006, 6:1031-1039. 16989585
40. Minev B Hipp J Firat H Schmidt JD Langlade-Demoyen P Zanetti M Cytotoxic T cell immunity against telomerase reverse transcriptase in humans Proceedings of the National Academy of Sciences of the United States of America 2000, 97:4796-4801. 18312 10759561
41. Vonderheide RH Anderson KS Hahn WC Butler MO Schultze JL Nadler LM Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase Clinical Cancer Research 2001, 7:3343-3348. 11705846
42. Vonderheide RH Domchek SM Schultze JL George DJ Hoar KM Chen DY Stephans KF Masutomi K Loda M Xia ZN et al.: Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes Clinical Cancer Research 2004, 10:828-839. 14871958
43. Jonuleit H Giesecke-Tuettenberg A Tuting T Thurner-Schuler B Stuge TB Paragnik L Kandemir A Lee PP Schuler G Knop J Enk AH A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection Int J Cancer 2001, 93(2):243-251. 11410873
44. Sun JC Williams MA Bevan MJ CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection[see comment] Nature Immunology 2004, 5:927-933. 15300249
45. Smith CM Wilson NS Waithman J Villadangos JA Carbone FR Heath WR Belz GT Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity[see comment] Nature Immunology 2004, 5:1143-1148. 15475958
46. Castano AP Mroz P Wu MX Hamblin MR Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model Proc Natl Acad Sci USA 2008, 105:5495-5500. 2291083 18378905
47. Heier I Hofgaard PO Brandtzaeg P Jahnsen FL Karlsson M Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma Clin Exp Immunol 2008, 152:381-387. 18341610
48. Sharma S Dominguez AL Lustgarten J High accumulation of T regulatory cells prevents the activation of immune responses in aged animals J Immunol 2006, 177:8348-8355. 17142731
49. Trzonkowski P Szmit E Myliwska J Myliwski A CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence Clinical Immunology 2006, 119:307-316. 16545982
50. Mahnke K Schonfeld K Fondel S Ring S Karakhanova S Wiedemeyer K Bedke T Johnson TS Storn V Schallenberg S Enk AH Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro Int J Cancer 2007, 120:2723-2733. 17315189
51. Lord R Nair S Schache A Spicer J Somaihah N Khoo V Pandha H Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study Journal of Urology 2007, 177:2136-2140. discussion 2140 17509300
52. Schroers R Shen L Rollins L Rooney CM Slawin K Sonderstrup G Huang XF Chen S-Y Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes[erratum appears in Clin Cancer Res. 2004 May 15;10(10):3576] Clinical Cancer Research 2003, 9:4743-4755. 14581345
53. Addison EG North J Bakhsh I Marden C Haq S Al-Sarraj S Malayeri R Wickremasinghe RG Davies JK Lowdell MW Ligation of CD8 alpha on human natural killer cells prevents activation-induced apoptosis and enhances cytolytic activity Immunology 2005, 116:354-361. 1802415 16236125
54. Lim HW Hillsamer P Banham AH Kim CH Cutting edge: Direct suppression of B cells by CD4+ CD25+ regulatory T cells J Immunol 2005, 175(7):4180-4183. 16177055
55. Fletcher TM Telomerase: A potential therapeutic target for cancer Expert Opinion on Therapeutic Targets 2005, 9:457-469. 15948667
56. Shay JW Bacchetti S A survey of telomerase activity in human cancer European Journal of Cancer 1997, 33:787-791. 9282118
57. Beatty GL Vonderheide RH Telomerase as a universal tumor antigen for cancer vaccines Expert Rev Vaccines 2008, 7:881-887. 18767939
58. Nair SKBD Morse M Induction of primary carcinoembryonic (CEA) specific cytotoxic T lymphocytes invitro using human dendritic cells transfected with RNA Nature Biotechnology 1998, 16:364-369. 9555728
59. Morse MA Lyerly HK Gilboa E Thomas E Nair SK Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells Cancer Res 1998, 58:2965-2968. 9679955
60. Schaft N Dorrie J Thumann P Beck VE Muller I Schultz ES Kampgen E Dieckmann D Schuler G Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation J Immunol 2005, 174:3087-3097. 15728524
61. Busch DH Kerksiek KM Pamer EG Differing roles of inflammation and antigen in T cell proliferation and memory generation J Immunol 2000, 164:4063-4070. 10754299
62. Bachmann MF Beerli RR Agnellini P Wolint P Schwarz K Oxenius A Long-lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation Eur J Immunol 2006, 36:842-854. 16552716
63. Wilson NS Villadangos JA Regulation of antigen presentation and cross-presentation in the dendritic cell network: Facts, hypothesis, and immunological implications Adv Immunol 2005, 86:241-305. 15705424
64. Wang RF Wang HY Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells Nat Biotechnol 2002, 20:149-154. 11821860
65. Ludewig B McCoy K Pericin M Ochsenbein AF Dumrese T Odermatt B Toes RE Melief CJ Hengartner H Zinkernagel RM Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells J Immunol 2001, 166:3678-3687. 11238607
66. He Y Zhang J Mi Z Robbins P Falo LD Jr Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity J Immunol 2005, 174(6):3808-3817. 15749922
67. Parkhurst MR Riley JP Igarashi T Li Y Robbins PF Rosenberg SA Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase Clinical Cancer Research 2004, 10:4688-4698. 2374668 15269141
68. Ayyoub M Migliaccio M Guillaume P Lienard D Cerottini JC Romero P Levy F Speiser DE Valmori D Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing European Journal of Immunology 2001, 31:2642-2651. 11536162
69. Purbhoo MA Li Y Sutton DH Brewer JE Gostick E Bossi G Laugel B Moysey R Baston E Liddy N et al.: The HLA A*0201-restricted hTERT540-548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor Molecular Cancer Therapeutics 2007, 6:2081-2091. 17620437
70. Brunsvig PF Aamdal S Gjertsen MK Kvalheim G Markowski-Grimsrud CJ Sve I Dyrhaug M Trachsel S Moller M Eriksen JA Gaudernack G Telomerase peptide vaccination: A phase I/II study in patients with non-small cell lung cancer Cancer Immunology, Immunotherapy 2006, 55:1553-1564.
71. Wenandy L Sorensen RB Sengelov L Svane IM thor Straten P Andersen MH The immunogenicity of the hTERT540-548 peptide in cancer Clin Cancer Res 2008, 14:4-7. 18172245
72. Lapenta C Santini SM Logozzi M Spada M Andreotti M Di Pucchio T Parlato S Belardelli F Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha Journal of Experimental Medicine 2003, 198:361-367. 2194078 12874266
73. Tosi D Valenti R Cova A Sovena G Huber V Pilla L Arienti F Belardelli F Parmiani G Rivoltini L Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens J Immunol 2004, 172(9):5363-5370. 15100276
74. Zhou LJTT CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells Proc Natl Acad Sci USA 1996, 93:2588-2592. 39841 8637918
75. Filaci G Fravega M Setti M Traverso P Millo E Fenoglio D Negrini S Ferrera F Romagnoli A Basso M et al.: Frequency of telomerase-specific CD8+ T lymphocytes in cancer patients Blood 2006, 107:1505-1512. 16249379
76. Cortez-Gonzalez X Zanetti M Telomerase immunity from bench to bedside: round one Journal of Translational Medicine 2007, 5:12. 1839079 17324292
77. Castellino F Germain RN Cooperation between CD4+ and CD8+ T cells: When, where and how Annual Review of Immunology 2006, 24:519-540. 16551258
78. Kumaraguru U Banerjee K Rouse BT In vivo rescue of defective memory CD8(+) T cells by cognate helper T cells Journal Of Leukocyte Biology 2005, 78:879-887. 16081600
79. Kumaraguru U Suvas S Biswas PS Azkur AK Rouse BT Concomitant helper response rescues otherwise low avidity CD8(+) memory CTLs to become efficient effectors in vivo J Immunol 2004, 172(6):3719-3724. 15004176
80. Corthay A Skovseth DK Lundin KU Rosjo E Omholt H Hofgaard PO Haraldsen G Bogen B Primary antitumor immune response mediated by CD4(+) T cells Immunity 2005, 22:371-383. 15780993
81. Hokey DA Larregina AT Erdos G Watkins SC Falo LD Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity Cancer Research 2005, 65:10059-10067. 16267032
82. van Oijen M Bins A Elias S Sein J Weder P de Gast G Mallo H Gallee M Van Tinteren H Schumacher T Haanen J On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients Clin Cancer Res 2004, 10:4754-4760. 15269149
83. Yamshchikov G Thompson L Ross WG Galavotti H Aquila W Deacon D Caldwell J Patterson JW Hunt DF Slingluff CL Jr Analysis of a natural immune response against tumor antigens in a melanoma survivor: Lessons applicable to clinical trial evaluations Clin Cancer Res 2001, 7:909s-916s. 11300491
84. Romero P Dunbar PR Valmori D Pittet M Ogg GS Rimoldi D Chen JL Lienard D Cerottini JC Cerundolo V Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes J Exp Med 1998, 188:1641-1650. 2212507 9802976
85. Haanen JBAG Baars A Gomez R Weder P Smits M de Gruijl TD von Blomberg BME Bloemena E Scheper RJ van Ham SM et al.: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients Cancer Immunology, Immunotherapy 2006, 55:451-458.
86. Chen SS Chen KK Lin AT Chang YH Wu HH Chang LS The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis BJU Int 2002, 89:710-713. 11966629
87. Stamey TA Kabalin JN Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients J Urol 1989, 141:1070-1075. 2468794
88. Stamey TA Kabalin JN Ferrari M Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients J Urol 1989, 141:1084-1087. 2468796
89. Stamey TA Kabalin JN Ferrari M Yang N Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients J Urol 1989, 141:1088-1090. 2468797
90. Stamey TA Kabalin JN McNeal JE Johnstone IM Freiha F Redwine EA Yang N Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients J Urol 1989, 141:1076-1083. 2468795
91. Nosari A Nichelatti M De Gasperi A Nador G Anghilieri M Mazza E Cozzi P Mancini V Miqueleiz S Bettinelli L et al.: Incidence of sepsis in central venous catheter-bearing patients with hematologic malignancies: preliminary results J Vasc Access 2004, 5:168-173. 16596561
92. Bona RD Central line thrombosis in patients with cancer Curr Opin Pulm Med 2003, 9:362-366. 12904704
93. Lutsiak MEC Semnani RT De Pascalis R Kashmiri SVS Schlom J Sabzevari H Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 2005, 105:2862-2868. 15591121
94. Schiavoni G Mattei F Di Pucchio T Santini SM Bracci L Belardelli F Proietti E Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: Implications for strategies of chemoimmunotherapy of cancer Blood 2000, 95:2024-2030. 10706870
95. Ghiringhelli F Menard C Puig PE Ladoire S Roux S Martin F Solary E Le Cesne A Zitvogel L Chauffert B Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 2007, 56(5):641-648. 16960692
96. Ghiringhelli F Larmonier N Schmitt E Parcellier A Cathelin D Garrido C Chauffert B Solary E Bonnotte B Martin F CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative European Journal of Immunology 2004, 34:336-344. 14768038
97. Eklund JW Kuzel TM Denileukin diftitox: A concise clinical review Expert Rev Anticancer Ther 2005, 5:33-38. 15757436
98. Frankel AE Surendranathan A Black JH White A Ganjoo K Cripe LD Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia Cancer 2006, 106:2158-2164. 16586495
99. Ho VT Zahrieh D Hochberg E Micale E Levin J Reynolds C Steckel S Cutler C Fisher DC Lee SJ et al.: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Blood 2004, 104:1224-1226. 15113758
100. Rasku MA Clem AL Telang S Taft B Gettings K Gragg H Cramer D Lear SC McMasters KM Miller DM Chesney J Transient T cell depletion causes regression of melanoma metastases J Transl Med 2008, 6:12. 2330026 18334033
101. Zou W Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 2006, 6:295-307. 16557261